Advertisement

Breast Cancer Research and Treatment

, Volume 170, Issue 2, pp 271–277 | Cite as

A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients

  • Hao Cai
  • Wenbing Guo
  • Shuobo Zhang
  • Na Li
  • Xianlong Wang
  • Huaping Liu
  • Rou Chen
  • Shanshan Wang
  • Zheng Guo
  • Jing Li
Preclinical study

Abstract

Purpose

Immunohistochemistry (IHC) assessment of the estrogen receptor (ER) status has low consensus among pathologists. Quantitative transcriptional signatures are highly sensitive to the measurement variation and sample quality. Here, we developed a robust qualitative signature, based on within-sample relative expression orderings (REOs) of genes, to reclassify ER status.

Methods

From the gene pairs with significantly stable REOs in ER+ samples and reversely stable REOs in ER− samples, concordantly identified from four datasets, we extracted a signature to determine a sample’s ER status through evaluating whether the REOs within the sample significantly match with the ER+ REOs or the ER− REOs.

Results

A signature with 112 gene pairs was extracted. It was validated through evaluating whether the reclassified ER+ or ER− patients could benefit from tamoxifen therapy or neoadjuvant chemotherapy. In three datasets for IHC-determined ER+ patients treated with post-operative tamoxifen therapy, 11.6–12.4% patients were reclassified as ER− by the signature and, as expected, they had significantly worse recurrence-free survival than the ER+ patients confirmed by the signature. On another hand, in two datasets for IHC-determined ER− patients treated with neoadjuvant chemotherapy, 18.8 and 7.8% patients were reclassified as ER+ and, as expected, their pathological complete response rate was significantly lower than that of the other ER− patients confirmed by the signature.

Conclusions

The REO-based signature can provide an objective assessment of ER status of breast cancer patients and effectively reduce misjudgments of ER status by IHC.

Keywords

Breast cancer Relative expression orderings Estrogen receptor Immunohistochemistry 

Abbreviations

ER

Estrogen receptor

IHC

Immunohistochemical

REO

Relative expression ordering

pCR

Pathological complete response

RD

Residual disease

GEO

Gene expression omnibus

RMA

Robust multichip average algorithm

RFS

Relapse-free survival

HR

Hazard ratio

CI

Confidence interval

FDR

False discovery rate

Notes

Acknowledgments

The research was supported by Grants from the National Natural Science Foundation of China (Grant No. 81202101, 81172531, 61602119, and 30930038) and the Joint Technology Innovation Fund of Fujian Province (Grant number: 2016Y9044).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10549_2018_4758_MOESM1_ESM.doc (112 kb)
Supplementary material 1 (DOC 112 kb)

References

  1. 1.
    Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMedGoogle Scholar
  2. 2.
    American Cancer Society. Available from: https://www.cancer.org/cancer/breast-cancer.html
  3. 3.
    Gancberg D, Jarvinen T, di Leo A et al (2002) Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat 74(2):113–120CrossRefPubMedGoogle Scholar
  4. 4.
    Diaz LK, Sahin A, Sneige N (2004) Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol 8(1):23–27CrossRefPubMedGoogle Scholar
  5. 5.
    Kirkegaard T, Edwards J, Tovey S et al (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48(7):787–794CrossRefPubMedGoogle Scholar
  6. 6.
    Arihiro K, Umemura S, Kurosumi M et al (2007) Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays. Am J Clin Pathol 127(3):356–365CrossRefPubMedGoogle Scholar
  7. 7.
    Press MF, Slamon DJ, Flom KJ et al (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20(14):3095–3105CrossRefPubMedGoogle Scholar
  8. 8.
    Fitzgibbons PL, Murphy DA, Hammond ME et al (2010) Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med 134(6):930–935PubMedGoogle Scholar
  9. 9.
    Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Orlando L, Viale G, Bria E et al (2016) Discordance in pathology report after central pathology review: implications for breast cancer adjuvant treatment. Breast 30:151–155CrossRefPubMedGoogle Scholar
  11. 11.
    Dubowitz V (1991) A new muscle journal for the nineties. Neuromuscul Disord: NMD 1(1):1–2CrossRefPubMedGoogle Scholar
  12. 12.
    Sheffield BS, Kos Z, Asleh-Aburaya K et al (2016) Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. Breast Cancer Res Treat 155(3):483–490CrossRefPubMedGoogle Scholar
  13. 13.
    Gong Y, Yan K, Lin F et al (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8(3):203–211CrossRefPubMedGoogle Scholar
  14. 14.
    Badve SS, Baehner FL, Gray RP et al (2008) Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26(15):2473–2481CrossRefPubMedGoogle Scholar
  15. 15.
    Roepman P, Horlings HM, Krijgsman O et al (2009) Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 15(22):7003–7011CrossRefPubMedGoogle Scholar
  16. 16.
    Du X, Li XQ, Li L et al (2013) The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis. Breast Cancer Res Treat 138(1):59–67CrossRefPubMedGoogle Scholar
  17. 17.
    Tramm T, Hennig G, Kyndi M et al (2013) Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection. Virchows Archiv 463(6):775–786CrossRefPubMedGoogle Scholar
  18. 18.
    Wilson TR, Xiao Y, Spoerke JM et al (2014) Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. Breast Cancer Res Treat 148(2):315–325CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Consortium M, Shi L, Reid LH et al (2006) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24(9):1151–1161Google Scholar
  20. 20.
    Gazdar AF, Schiller JH (2011) Predictive and prognostic factors for non-small cell lung cancer–potholes in the road to the promised land. J Natl Cancer Inst 103(24):1810–1811CrossRefPubMedGoogle Scholar
  21. 21.
    Qi L, Chen L, Li Y et al (2016) Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer. Brief Bioinform 17(2):233–242CrossRefPubMedGoogle Scholar
  22. 22.
    Lu X, Lu X, Wang ZC et al (2008) Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 108(2):191–201CrossRefPubMedGoogle Scholar
  23. 23.
    Wang D, Cheng L, Wang M et al (2011) Extensive increase of microarray signals in cancers calls for novel normalization assumptions. Comput Biol Chem 35(3):126–130CrossRefPubMedGoogle Scholar
  24. 24.
    Nygaard V, Rodland EA, Hovig E (2016) Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses. Biostatistics 17(1):29–39PubMedGoogle Scholar
  25. 25.
    Eddy JA, Sung J, Geman D et al (2010) Relative expression analysis for molecular cancer diagnosis and prognosis. Technol Cancer Res Treat 9(2):149–159CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Patil P, Bachant-Winner PO, Haibe-Kains B et al (2015) Test set bias affects reproducibility of gene signatures. Bioinformatics 31(14):2318–2323CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cheng J, Guo Y, Gao Q et al (2017) Circumvent the uncertainty in the applications of transcriptional signatures to tumor tissues sampled from different tumor sites. Oncotarget 8(18):30265–30275PubMedPubMedCentralGoogle Scholar
  28. 28.
    Chen R, Guan Q, Cheng J et al (2017) Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples. Oncotarget 8(4):6652–6662PubMedGoogle Scholar
  29. 29.
    Liu H, Li Y, He J et al (2017) Robust transcriptional signatures for low-input RNA samples based on relative expression orderings. BMC Genom 18(1):913CrossRefGoogle Scholar
  30. 30.
    Ao L, Song X, Li X et al (2016) An individualized prognostic signature and multiomics distinction for early stage hepatocellular carcinoma patients with surgical resection. Oncotarget 7(17):24097–24110CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Li X, Cai H, Zheng W et al (2016) An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups. Oncotarget 7(8):8743–8755PubMedPubMedCentralGoogle Scholar
  32. 32.
    Qi L, Li T, Shi G et al (2017) An individualized gene expression signature for prediction of lung adenocarcinoma metastases. Mol Oncol 11(11):1630–1645CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Guan Q, Chen R, Yan H et al (2016) Differential expression analysis for individual cancer samples based on robust within-sample relative gene expression orderings across multiple profiling platforms. Oncotarget 7(42):68909–68920CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mouttet D, Lae M, Caly M et al (2016) Estrogen-receptor, progesterone-receptor and HER2 status determination in invasive breast cancer. Concordance between immuno-histochemistry and MapQuant microarray based assay. PLoS ONE 11(2):e0146474CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Wesseling J, Tinterri C, Sapino A et al (2016) An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. Virchows Archiv 469(3):297–304CrossRefPubMedGoogle Scholar
  36. 36.
    Viale G, de Snoo FA, Slaets L et al (2017) Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. Breast Cancer Res TreatGoogle Scholar
  37. 37.
    Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784Google Scholar
  38. 38.
    Hackshaw A, Roughton M, Forsyth S et al (2011) Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 29(13):1657–1663CrossRefPubMedGoogle Scholar
  39. 39.
    Blamey RW, Bates T, Chetty U et al (2013) Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 49(10):2294–2302CrossRefPubMedGoogle Scholar
  40. 40.
    Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24(7):1037–1044CrossRefPubMedGoogle Scholar
  42. 42.
    Kaufmann M, von Minckwitz G, Smith R et al (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21(13):2600–2608CrossRefPubMedGoogle Scholar
  43. 43.
    Irizarry RA, Hobbs B, Collin F et al (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4(2):249–264CrossRefPubMedGoogle Scholar
  44. 44.
    Bahn AK (1969) Application of binomial distribution to medicine: comparison of one sample proportion to an expected proportion (for small samples). Evaluation of a new treatment. Evaluation of a risk factor. J Am Med Women’s Assoc 24(12):957–966Google Scholar
  45. 45.
    Schweder T, Spjøtvoll E (1982) A class of rank test procedures for censored survival data. Biometrika 69(3):553–566Google Scholar
  46. 46.
    Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate—a practical and powerful approach to multiple testing. J R Stat Soc 57(1):289–300Google Scholar
  47. 47.
    National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
  48. 48.
    Yi M, Huo L, Koenig KB et al (2014) Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 25(5):1004–1011CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, Key Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical SciencesFujian Medical UniversityFuzhouChina
  2. 2.Fujian Key Laboratory of Tumor MicrobiologyFujian Medical UniversityFuzhouChina
  3. 3.Department of Systems Biology, College of Bioinformatics Science and TechnologyHarbin Medical UniversityHarbinChina
  4. 4.Key Laboratory of Ministry of Education for Arrhythmias, Shanghai East HospitalTongji University School of MedicineShanghaiChina

Personalised recommendations